New Press Release
The U.S. Food and Drug Administration (FDA) has approved Sandoz biosimilar Enzeevu™ (aflibercept-abzv) 2 mg vial kit and pre-filled syringe for intravitreal injection. Enzeevu is indicated to improve and maintain visual acuity in patients with neovascular age-related macular degeneration.
With this approval, Sandoz is proud to offer people living with neovascular age-related macular degeneration another treatment option that, upon launch, could help improve access and timeliness of care for those in need of treatment. By prioritizing patient access to critical biologic treatments in the ophthalmology space, we can significantly enhance visual health outcomes in the U.S., reduce health disparities, and improve overall quality of life for individuals at risk of vision loss.
For more details on this FDA approval, please see our full press release.